BioPharmSignal logoBioPharmSignal

Biotech News

Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results

SOLIGENIX (SNGX)SOLIGENIXEarnings

SNGX (SNGX) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is sngx.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

SNGXSOLIGENIX2026-05-08 11:30 EST

Soligenix Announces Recent Updates and First Quarter 2026 Financial Results

SABSSAB Biotherapeutics2026-05-12 11:30 EST

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

AVTXAvalo Therapeutics2026-05-13 11:00 EST

Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates

GPCRStructure Therapeutics2026-05-07 20:06 EST

Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

ZURAZura Bio2026-05-07 11:30 EST

Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates

KNSAKiniksa2026-04-28 11:30 EST

Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution

AVTXAvalo Therapeutics2026-03-23 11:00 EST

Avalo Therapeutics Reports 2025 Financial Results and Recent Business Updates

ZURAZura Bio2026-03-19 20:05 EST

Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates

IMVTImmunovant2026-07-23 20:05 EST

Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026

ARGXArgenx2026-07-23 05:00 EST

argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update

View all latest news

SOLIGENIX

Soligenix is a specialty biotechnology company focused on inflammatory diseases, biodefense, and orphan indications. Its story reflects a broad but still narrow small-cap pipeline targeting areas with high unmet need.

Recent company news

SNGXSOLIGENIX2026-06-08 11:30 EST

Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine

SNGXSOLIGENIX2026-05-26 11:30 EST

Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo

SNGXSOLIGENIX2026-05-08 11:30 EST

Soligenix Announces Recent Updates and First Quarter 2026 Financial Results

SNGXSOLIGENIX2026-04-28 11:30 EST

Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma

SNGXSOLIGENIX2026-04-02 11:30 EST

Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy

Stock data

Close
0.36 USD
Market cap
11.1M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States